Free Trial
NASDAQ:ARAY

Accuray (ARAY) Stock Price, News & Analysis

Accuray logo
$1.90 -0.01 (-0.26%)
As of 10:24 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Accuray Stock (NASDAQ:ARAY)

Key Stats

Today's Range
$1.89
$1.93
50-Day Range
$1.74
$2.69
52-Week Range
$1.40
$2.95
Volume
39,828 shs
Average Volume
671,123 shs
Market Capitalization
$194.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Remove Ads

Accuray Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
31st Percentile Overall Score

ARAY MarketRank™: 

Accuray scored higher than 31% of companies evaluated by MarketBeat, and ranked 763rd out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Accuray.

  • Earnings Growth

    Earnings for Accuray are expected to grow by 1,100.00% in the coming year, from $0.01 to $0.12 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Accuray is -38.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Accuray is -38.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Accuray has a P/B Ratio of 4.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Accuray's valuation and earnings.
  • Percentage of Shares Shorted

    4.37% of the float of Accuray has been sold short.
  • Short Interest Ratio / Days to Cover

    Accuray has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Accuray has recently increased by 2.63%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Accuray does not currently pay a dividend.

  • Dividend Growth

    Accuray does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.37% of the float of Accuray has been sold short.
  • Short Interest Ratio / Days to Cover

    Accuray has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Accuray has recently increased by 2.63%, indicating that investor sentiment is decreasing.
  • Search Interest

    Only 2 people have searched for ARAY on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Accuray insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.23% of the stock of Accuray is held by insiders.

  • Percentage Held by Institutions

    64.08% of the stock of Accuray is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Accuray's insider trading history.
Receive ARAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

ARAY Stock News Headlines

Accuray (NASDAQ:ARAY) Upgraded to Buy at StockNews.com
Elon Musk is helping print “new gold”
MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.
Roth MKM Remains a Buy on Accuray (ARAY)
See More Headlines

ARAY Stock Analysis - Frequently Asked Questions

Accuray's stock was trading at $1.98 at the start of the year. Since then, ARAY shares have decreased by 4.3% and is now trading at $1.8950.
View the best growth stocks for 2025 here
.

Accuray Incorporated (NASDAQ:ARAY) issued its earnings results on Wednesday, February, 5th. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.03. Accuray had a negative trailing twelve-month return on equity of 9.75% and a negative net margin of 0.96%.

Accuray subsidiaries include Morphormics Inc., TomoTherapy Incorporated, Accuray Accelerator Technology (Chengdu) Company Limited, Accuray Asia Ltd., Accuray Belgium BVBA, Accuray Brasil Comércio, Accuray Cayman Islands, and others.

Accuray's top institutional shareholders include Heartland Advisors Inc. (3.72%), Renaissance Technologies LLC (2.90%), Geode Capital Management LLC (2.13%) and D. E. Shaw & Co. Inc. (1.74%). Insiders that own company stock include Suzanne C Winter, Sandeep Chalke, Joseph E Whitters, Jesse Chew, Michael Hoge, Ali Pervaiz, Patrick Spine and Gina Corradetti.
View institutional ownership trends
.

Shares of ARAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Accuray investors own include Waste Connections (WCN), American Water Works (AWK), Voyager Therapeutics (vygr), AUO (AUOTY), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
2/05/2025
Today
3/25/2025
Next Earnings (Estimated)
4/29/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ARAY
Employees
1,040
Year Founded
1990

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
189.50
P/E Growth
N/A
Net Income
$-15,550,000.00
Pretax Margin
-0.47%

Debt

Sales & Book Value

Annual Sales
$453.14 million
Price / Cash Flow
N/A
Book Value
$0.45 per share
Price / Book
4.21

Miscellaneous

Free Float
98,481,000
Market Cap
$194.86 million
Optionable
Optionable
Beta
1.46

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ARAY) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners